Company: SGX Pharmaceuticals
Starting stock price: $3.314
Ending stock price: $4.76
Percent Change: 43.81%
Details: SGX is focused on developing cancer drugs, and uses its FAST technology to identify and optimize small molecule fragments that bind to specific targets. In 2007 SGX filed an IND for SGX523 for solid tumors. The company also has a number of preclinical programs for relapsed/refractory chronic myelogenous leukemia (CML) and front-line CML.
SGX Initiates Phase I Trials for SGX523. Report
SGX shares tank on late-stage trial failure. Report